Expanding the PSA-Activated Prodrug Platform
Innovex is pursuing a staged strategy to validate PSA-mediated activation, extend the platform to additional payload classes, and explore complementary targeting approaches.
A Staged Platform Strategy
01
Validate the Platform
Establishing rigorous proof-of-concept that PSA-mediated activation can selectively release therapeutic agents in the intended biological environment, providing the scientific foundation for broader development.
02
Expand Payload Options
Extending the platform architecture to accommodate a broader range of therapeutic payloads, increasing versatility and enabling the technology to address diverse disease contexts.
03
Explore Complementary Targeting Approaches
Investigating additional targeting strategies that could work in concert with PSA-mediated activation, broadening the platform’s reach and potential applicability.
How Expansion Opportunities Will Be Prioritized
01
Systemic Stability
Candidate payloads must demonstrate sufficient stability in circulation to reach the target site intact, limiting premature degradation or off-target activity before enzymatic activation occurs.
02
PSA-Dependent Activation
Each payload class is evaluated for compatibility with PSA-mediated cleavage, ensuring that therapeutic release remains tightly coupled to the enzymatic trigger that defines the platform’s selectivity.
03
Tumor Exposure
Prioritized payloads must achieve meaningful concentrations within the tumor microenvironment following activation, supporting the premise that localized release can translate into relevant biological effect.
04
Therapeutic-Index Potential
The overall balance between anticipated efficacy and tolerability is assessed across candidate payload classes, with preference given to those offering the widest potential separation between therapeutic and adverse effects.
Building Through Focused Execution
Innovex will advance platform-expansion opportunities selectively, guided by scientific differentiation, development feasibility, and therapeutic potential.
